PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for patients who are...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cochrane Database Syst Rev
Asıl Yazarlar: Schmidt, Amand F, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, Juan P
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2017
Konular:
Medicine General & Introductory Medical Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478267/
https://ncbi.nlm.nih.gov/pubmed/28453187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller